Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Granulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma

Bone Marrow Transplantation volume 40, pages 1147–1155 (2007)Cite this article

Abstract

High-dose chemotherapy is an established treatment for patients with myeloma. In randomized trials it has been shown to prolong disease-free survival by around 1 year compared to patients receiving chemotherapy alone. Physically and psychologically high-dose therapy takes its toll on the patient who may be in hospital for around 3 weeks and take some weeks or months to convalesce after discharge. Granulocyte colony stimulating factors and erythropoietic stimulating agents will speed neutrophil and red cell recovery, respectively, when used at an appropriate time after the high-dose chemotherapy. The clinical value of these laboratory findings is uncertain and the role of these agents after high-dose chemotherapy remains a subject for debate.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Gratwohl A, Baldomero H, Passweg J, Frassoni F, Niederwieser D, Schmitz N et al. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia 2003; 17: 941–959.

    Article  CAS  PubMed  Google Scholar 

  2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  3. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  4. Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755–3759.

    Article  CAS  PubMed  Google Scholar 

  5. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.

    Article  CAS  PubMed  Google Scholar 

  6. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G . Reduced intensity conditioning for myeloma: lower non-relapse mortality but higher relapse rates compared to myeloablative conditioning. Blood 2007; 109: 3588–3594.

    Article  CAS  PubMed  Google Scholar 

  7. Nicola NA, Metcalf D, Matsumoto M, Johnson GR . Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. J Biol Chem 1983; 258: 9017–9023.

    Article  CAS  PubMed  Google Scholar 

  8. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G . Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88: 1907–1929.

    Article  CAS  PubMed  Google Scholar 

  9. Avalos BR . Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 1996; 88: 761–777.

    Article  CAS  PubMed  Google Scholar 

  10. Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84: 1737–1746.

    Article  CAS  PubMed  Google Scholar 

  11. Xu S, Hoglund M, Venge P . The effect of granulocyte colony-stimulating factor (G-CSF) on the degranulation of secondary granule proteins from human neutrophils in vivo may be indirect. Br J Haematol 1996; 93: 558–568.

    Article  CAS  PubMed  Google Scholar 

  12. Chakraborty A, Hentzen ER, Seo SM, Smith CW . Granulocyte colony-stimulating factor promotes adhesion of neutrophils. Am J Physiol Cell Physiol 2003; 284: C103–C110.

    Article  CAS  PubMed  Google Scholar 

  13. Villalta F, Kierszenbaum F . Effects of human colony-stimulating factor on the uptake and destruction of a pathogenic parasite (Trypanosoma cruzi) by human neutrophils. J Immunol 1986; 137: 1703–1707.

    CAS  PubMed  Google Scholar 

  14. Begley CG, Lopez AF, Nicola NA, Warren DJ, Vadas MA, Sanderson CJ et al. Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. Blood 1986; 68: 162–166.

    Article  CAS  PubMed  Google Scholar 

  15. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L . Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24: 5207–5215.

    Article  CAS  PubMed  Google Scholar 

  16. Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplant 2004; 34: 955–962.

    Article  CAS  PubMed  Google Scholar 

  17. Luce BR, Singer JW, Weschler JM, Buckner CD, Sheingold SH, Shannon-Dorcy K et al. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial. Pharmacoeconomics 1994; 6: 42–48.

    Article  CAS  PubMed  Google Scholar 

  18. Lee SM, Radford JA, Dobson L, Huq T, Ryder WD, Pettengell R et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 1998; 77: 1294–1299.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Brice P, Godin S, Libert O, Marolleau JP, Makki J, Extra JM et al. Effect of lenograstim on the cost of autologous bone marrow transplantation. A preliminary communication. Pharmacoeconomics 1995; 7: 238–241.

    Article  CAS  PubMed  Google Scholar 

  20. Ojeda E, Garcia-Bustos J, Aguado M, Arrieta R, Quevedo E, Yuste VJ et al. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant 1999; 24: 601–607.

    Article  CAS  PubMed  Google Scholar 

  21. Przepiorka D, Smith TL, Folloder J, Anderlini P, Chan KW, Korbling M et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001; 97: 3405–3410.

    Article  CAS  PubMed  Google Scholar 

  22. Gonzalez-Vicent M, Madero L, Sevilla J, Ramirez M, Diaz MA . A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. Bone Marrow Transplant 2004; 34: 1077–1081.

    Article  CAS  PubMed  Google Scholar 

  23. Bence-Bruckler I, Bredeson C, Atkins H, McDiarmid S, Hamelin L, Hopkins H et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998; 22: 965–969.

    Article  CAS  PubMed  Google Scholar 

  24. Bolwell BJ, Pohlman B, Andresen S, Kalaycio M, Goormastic M, Wise K et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998; 21: 369–373.

    Article  CAS  PubMed  Google Scholar 

  25. Colby C, McAfee SL, Finkelstein DM, Spitzer TR . Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21: 1005–1010.

    Article  CAS  PubMed  Google Scholar 

  26. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187–3205.

    Article  CAS  PubMed  Google Scholar 

  27. Ravaud A, Chevreau C, Cany L, Houyau P, Dohollou N, Roche H et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. J Clin Oncol 1998; 16: 2930–2936.

    Article  CAS  PubMed  Google Scholar 

  28. Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez-Brea M et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995; 87: 803–808.

    Article  CAS  PubMed  Google Scholar 

  29. Vellenga E, Uyl-de Groot CA, de Wit R, Keizer HJ, Lowenberg B, ten Haaft MA et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 1996; 14: 619–627.

    Article  CAS  PubMed  Google Scholar 

  30. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B . Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005; 23: 4198–4214.

    Article  CAS  PubMed  Google Scholar 

  31. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002; 10: 181–188.

    Article  CAS  PubMed  Google Scholar 

  32. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416–423.

    Article  CAS  PubMed  Google Scholar 

  33. Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svennberg P et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II–IV. Bone Marrow Transplant 2003; 32: 217–223.

    Article  CAS  PubMed  Google Scholar 

  34. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza Jr FR, Ringden O et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872–4880.

    Article  PubMed  Google Scholar 

  35. Ho VT, Mirza NQ, Junco Dd D, Okamura T, Przepiorka D . The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant 2003; 32: 771–775.

    Article  CAS  PubMed  Google Scholar 

  36. Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 949–954.

    CAS  PubMed  Google Scholar 

  37. Nissen C . Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur J Cancer 1994; 30A (Suppl 3): S12–S14.

    CAS  PubMed  Google Scholar 

  38. Pedrazzoli P, Gibelli N, Pavesi L, Preti P, Piolini M, Bertolini F et al. Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. Anticancer Res 1996; 16: 1781–1785.

    CAS  PubMed  Google Scholar 

  39. Fischer JC, Frick M, Wassmuth R, Platz A, Punzel M, Wernet P . Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol 2005; 130: 740–746.

    Article  CAS  PubMed  Google Scholar 

  40. Hoglund M, Smedmyr B, Bengtsson M, Totterman TH, Cour-Chabernaud V, Yver A et al. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers—a comparative study. Eur J Haematol 1997; 59: 177–183.

    Article  CAS  PubMed  Google Scholar 

  41. Lefrere F, Bernard M, Audat F, Cavazzana-Calvo M, Belanger C, Hermine O et al. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients. Leuk Lymphoma 1999; 35: 501–505.

    Article  CAS  PubMed  Google Scholar 

  42. Kopf B, De Giorgi U, Vertogen B, Monti G, Molinari A, Turci D et al. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant 2006; 38: 407–412.

    Article  CAS  PubMed  Google Scholar 

  43. Bonig H, Silbermann S, Weller S, Kirschke R, Korholz D, Janssen G et al. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)—results of a prospective randomised monocentre study. Bone Marrow Transplant 2001; 28: 259–264.

    Article  CAS  PubMed  Google Scholar 

  44. Kim IH, Park SK, Suh OK, Oh JM . Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy. Curr Med Res Opin 2003; 19: 753–759.

    Article  CAS  PubMed  Google Scholar 

  45. Huttmann A, Schirsafi K, Seeber S, Bojko P . Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. J Cancer Res Clin Oncol 2005; 131: 152–156.

    Article  CAS  PubMed  Google Scholar 

  46. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724–1734.

    Article  CAS  PubMed  Google Scholar 

  47. Molineux G . The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004; 10: 1235–1244.

    Article  CAS  PubMed  Google Scholar 

  48. Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 2005; 35: 1165–1169.

    Article  CAS  PubMed  Google Scholar 

  49. Martino M, Pratico G, Messina G, Irrera G, Massara E, Messina G et al. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006; 77: 410–415.

    Article  CAS  PubMed  Google Scholar 

  50. Legros M, Fleury J, Bay JO, Choufi B, Basile M, Condat P et al. rhGM-CSF vs placebo following rhGM-CSF-mobilized PBPC transplantation: a phase III double-blind randomized trial. Bone Marrow Transplant 1997; 19: 209–213.

    Article  CAS  PubMed  Google Scholar 

  51. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580–585.

    Article  CAS  PubMed  Google Scholar 

  52. Bregni M, Siena S, Di Nicola M, Dodero A, Peccatori F, Ravagnani F et al. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. J Clin Oncol 1996; 14: 628–635.

    Article  CAS  PubMed  Google Scholar 

  53. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642–650.

    Article  CAS  PubMed  Google Scholar 

  54. Rauscher GH, Sandler DP, Poole C, Pankow J, Mitchell B, Bloomfield CD et al. Family history of cancer and incidence of acute leukemia in adults. Am J Epidemiol 2002; 156: 517–526.

    Article  PubMed  Google Scholar 

  55. Confer DL, Miller JP . Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 77–78; author reply 79–80.

    Article  PubMed  Google Scholar 

  56. Le Deley MC, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007; 25: 292–300.

    Article  CAS  PubMed  Google Scholar 

  57. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99: 196–205.

    Article  CAS  PubMed  Google Scholar 

  58. Law ML, Cai GY, Lin FK, Wei Q, Huang SZ, Hartz JH et al. Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism. Proc Natl Acad Sci USA 1986; 83: 6920–6924.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Lacombe C, Mayeux P . Biology of erythropoietin. Haematologica 1998; 83: 724–732.

    CAS  PubMed  Google Scholar 

  60. Kendall RG . Erythropoietin. Clin Lab Haematol 2001; 23: 71–80.

    Article  CAS  PubMed  Google Scholar 

  61. Inoue N, Takeuchi M, Ohashi H, Suzuki T . The production of recombinant human erythropoietin. Biotechnol Annu Rev 1995; 1: 297–313.

    Article  CAS  PubMed  Google Scholar 

  62. Romanowski RR, Sytkowski AJ . The molecular structure of human erythropoietin. Hematol Oncol Clin North Am 1994; 8: 885–894.

    Article  CAS  PubMed  Google Scholar 

  63. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100: 79–89.

    Article  CAS  PubMed  Google Scholar 

  64. Remy I, Wilson IA, Michnick SW . Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999; 283: 990–993.

    Article  CAS  PubMed  Google Scholar 

  65. Cheung JY, Miller BA . Molecular mechanisms of erythropoietin signaling. Nephron 2001; 87: 215–222.

    Article  CAS  PubMed  Google Scholar 

  66. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999; 274: 22165–22169.

    Article  CAS  PubMed  Google Scholar 

  67. Birgegard G, Gascon P, Ludwig H . Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. Eur J Haematol 2006; 77: 378–386.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Ludwig H, Pohl G, Osterborg A . Anemia in multiple myeloma. Clin Adv Hematol Oncol 2004; 2: 233–241.

    PubMed  Google Scholar 

  69. Ganz T . Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program 2006, 29–35.

    Article  Google Scholar 

  70. Silvestris F, Cafforio P, Tucci M, Dammacco F . Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 2002; 99: 1305–1313.

    Article  CAS  PubMed  Google Scholar 

  71. Ludwig H, Rai K, Blade J, Dammacco F, Degos L, Itri L et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J 2002; 3: 121–130.

    Article  CAS  PubMed  Google Scholar 

  72. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B . Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122: 386–393.

    Article  CAS  PubMed  Google Scholar 

  73. Dammacco F, Castoldi G, Rodjer S . Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001; 113: 172–179.

    Article  CAS  PubMed  Google Scholar 

  74. Link H, Boogaerts MA, Fauser AA, Slavin S, Reiffers J, Gorin NC et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994; 84: 3327–3335.

    Article  CAS  PubMed  Google Scholar 

  75. Martino M, Oliva E, Console G, Stelitano C, Fujo M, Messina G et al. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. Support Care Cancer 2005; 13: 182–187.

    Article  PubMed  Google Scholar 

  76. Baron F, Frere P, Fillet G, Beguin Y . Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. Clin Cancer Res 2003; 9: 5566–5572.

    CAS  PubMed  Google Scholar 

  77. Vanstraelen G, Baron F, Frere P, Hafraoui K, Fillet G, Beguin Y . Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation. Haematologica 2005; 90: 1269–1270.

    CAS  PubMed  Google Scholar 

  78. Biggs JC, Atkinson KA, Booker V, Concannon A, Dart GW, Dodds A et al. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. Bone Marrow Transplant 1995; 15: 129–134.

    CAS  PubMed  Google Scholar 

  79. Ivanov V, Faucher C, Mohty M, Bilger K, Ladaique P, Sainty D et al. Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 901–906.

    Article  CAS  PubMed  Google Scholar 

  80. Baron F, Frere P, Beguin Y . Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftment. Haematologica 2003; 88: 718–720.

    PubMed  Google Scholar 

  81. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P et al. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Eng J Med 2002; 346: 469–475.

    Article  CAS  Google Scholar 

  82. Crawford J . Erythropoietin: high profile, high scrutiny. J Clin Oncol 2007; 25: 1021–1023.

    Article  CAS  PubMed  Google Scholar 

  83. Bohlius J, Wilson J, Seidenfield J, Piper M, Schwarzer G, Sandercock J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98: 708–714.

    Article  CAS  PubMed  Google Scholar 

  84. Pagliuca A, Carrington PA, Pettengell R, Tule S, Keidan J . Guidelines on the use of colony-stimulating factors in haematological malignancies. Br J Haematol 2003; 123: 22–33.

    Article  PubMed  Google Scholar 

  85. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D . Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007; 39: 71–87.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, John Radcliffe Hospital, Oxford, UK

    T J Littlewood & G P Collins

Authors
  1. T J Littlewood
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G P Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T J Littlewood.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Littlewood, T., Collins, G. Granulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma. Bone Marrow Transplant 40, 1147–1155 (2007). https://doi.org/10.1038/sj.bmt.1705845

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705845

Keywords

Search

Advanced search

Quick links